Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective

Introduction: This study is one of the first real-world cost-effectiveness analyses of one-year adjuvant trastuzumab used in HER2-positive early female breast cancer in comparison to chemotherapy alone. It is just the second one in Europe, the first one in Cyprus, and the fourth one worldwide ever c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioannou, Savvas S., Marcou, Yiola, Kakouri, Eleni, Talias, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344736/
https://www.ncbi.nlm.nih.gov/pubmed/32560485
http://dx.doi.org/10.3390/ijerph17124339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344736/
https://www.ncbi.nlm.nih.gov/pubmed/32560485
http://dx.doi.org/10.3390/ijerph17124339

Ejemplares similares